Company Description

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.

Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.

The company was incorporated in 2019 and is based in Palo Alto, California.

Kalaris Therapeutics, Inc.

Country	United States
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	14
CEO	Andrew Oxtoby

Contact Details

Address: 628 Middlefield Road Palo Alto, California 94301 United States
Website	kalaristx.com

Stock Details

Ticker Symbol	KLRS
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001754068
CUSIP Number	482929106
ISIN Number	US4829291065
Employer ID	83-1971007
SIC Code	2836

Key Executives

Name	Position
Andrew Oxtoby	President, Chief Executive Officer and Director
Dr. Srinivas Akkaraju M.D., Ph.D.	Director and Co-Founder
Dr. Michael Philip Dybbs Ph.D.	Director and Co-Founder
Dr. Napoleone Ferrara M.D.	Independent Director and Co-Founder
Dr. Matthew Feinsod M.D.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Aug 13, 2025	10-Q	Quarterly Report
Aug 13, 2025	8-K	Current Report
Aug 13, 2025	8-K	Current Report
Jul 29, 2025	SCHEDULE 13G/A	Filing
Jul 1, 2025	ARS	Filing
Jul 1, 2025	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 1, 2025	DEF 14A	Other definitive proxy statements
Jun 20, 2025	8-K	Current Report
Jun 4, 2025	S-8	Securities to be offered to employees in employee benefit plans
May 15, 2025	SCHEDULE 13G/A	Filing

View All SEC Filings